Share

 
 

Want information on dosing?

Reimbursement & patient access?

See our Approved Products

References:

1.
Wierda WG, Keating MJ, O'Brien S. Chronic lymphocytic leukemias. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:2278-2292.
2.
Müller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008:180-182.
3.
http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_Are_the_Key_Statistics_About
_Chronic_Lymphocytic_Leukemia.asp. Accessed April 15, 2010.
4.
Surveillance, Epidemiology and End Results (SEER). Stat Fact Sheets—Chronic Lymphocytic Leukemia. http://seer.cancer.gov/statfacts/html/clyl.html. Accessed July 10, 2009.
5.
Horner MJ, Reis LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. http://seer.cancer.gov/faststats/selections.php?series=cancer. Accessed May 15, 2009.
6.
Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol. 2008;81:253-258.
7.
Zent CS, Kyasa MJ, Evans R, et al. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer. 2001;92:1325-1330.
8.
British Society for Haematology. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol. 2004;125:294-317.
9.
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood. 2008;111:5446-5456.
10.
Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109:4679-4685.
11.
Goede V, Hallek M. State-of-the-art treatment of chronic lymphocytic leukaemia. EJHP Pract. 2008;14:69-71.
12.
Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
13.
Dyer MJ, Gascoyne RD. Molecular biology, pathology, and cytogenetics of chronic lymphocytic leukemia. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: The McGraw-Hill Companies; 2007:213-223.
14.
Johnston JB. Chronic lymphocytic leukemia. In: Greer JP, Foerster J, Rodgers GM, et al, eds. Wintrobe's Clinical Hematology. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:2429-2463.
15.
Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21:956-964.
16.
Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
17.
Rai KR. A critical analysis of staging in CLL. In: Gale PR, Rai KR, eds. Chronic Lymphocytic Leukemia: Recent Progress and Future Direction. New York, NY: Alan R. Liss, Inc.; 1987:253-264. UCLA Symposium and Cellular Biology New Series; vol 59.
18.
Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.
19.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
20.
Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103:1202-1210.
21.
Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
22.
Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.
23.
Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
24.
Delgado J, Pratt G, Phillips N, et al. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol. 2009;145:801-805.
25.
Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood. 2006;108:853-861.
26.
Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
27.
Gribben JG. Molecular profiling in CLL. Hematology Am Soc Hematol Educ Program. 2008;444-449.
28.
Rai KR, Mehrotra B. Indications for treatment and treatment approach for chronic lymphocytic leukemia. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: The McGraw-Hill Companies; 2007:235-238.
29.
Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol. 2009;6:405-418.
30.
Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
31.
The NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. (Version 1.2010). © 2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed June 7, 2010.
32.
Quijano S, López A, Rasillo A, et al. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2008;74B:139-149.
33.
Lehmann S, Ogawa S, Raynaud SD, et al. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer. 2008;112:1296-1305.
34.
Del Giudice I, Morilla A, Osuji N, et al. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer. 2005;104:2124-2134.
35.
Porpaczy E, Bilban M, Heinze G, et al. Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12. Eur J Clin Invest. 2009;39:568-575.
36.
Eichhorst B, Geode V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:171-178.
37.
Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008;56:1926-1931.
38.
Kay NE. Treatment and evaluation of CLL: a complicated affair. Blood. 2006;107:848.
39.
US Food and Drug Administration Web site. http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/ index.cfm?fuseaction=Search.SearchResults_Browse&StartTow-201&StepSize=100. Accessed April 29, 2010.
40.
Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111:4916-4921.
41.
Kipps TJ. Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5566.
42.
Eichhorst B, Hallek M, Dreyling M. Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment, and follow-up. Ann Oncol. 2009;20(suppl 4):102-104.
43.
Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. J Clin Oncol. 1997;15:2736-2743.
44.
Montserrat E. Cell therapy: progress at last! Blood. 2005;105:2-3.
45.
Montserrat E. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal. J Clin Oncol. 2005;23:2884-2885.
46.
US National Institutes of Health. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov. Accessed June 8, 2010.
47.
Quintás-Cardama A, Wierda W, O'Brien S. Investigational immunotherapeutics for B-cell malignancies. J Clin Oncol. 2010;28:884-892.
48.
Kalaycio ME. Treatment of chronic lymphocytic leukemia. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: The McGraw-Hill Companies; 2007:245-249.
49.
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714-727.
50.
Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119:2143-2159.
51.
Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct- and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393-4402.
52.
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
53.
Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008;68:8384-8392.
54.
Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359:613-626.
55.
Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009;69:2358-2364.
56.
Danilov AV, Danilova OV, Klein AK, Huber BT. Molecular pathogenesis of chronic lymphocytic leukemia. Curr Molec Med. 2006;6:665-675.
57.
Lin TS. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies. Clin Lymphoma Myeloma. 2008;8(suppl 4):S137-S143.
58.
O'Brien S. New agents in the treatment of CLL. Hematology Am Soc Hematol Educ Program. 2008;457-464.
59.
Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 2003;3:213-217.
60.
Castro JE, Prada CE, Loria O, et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood. 2005;106:2506-2512.
61.
Powis G, Ihle N, Kirkpatrick DL. Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res. 2006;12:2964-2966.
62.
Niedermeier M, Hennessy BT, Knight ZA, et al. Isoform-selective phosphoinositide 3´-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009;113:5549-5557.
63.
Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103-112.
64.
Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006;176:5715-5719.
65.
Leseux L, Hamdi SM, al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006;108:4156-4162.
66.
Quiroga MP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009;114:1029-1037.
67.
Nabhan C, Coutré S, Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Br J Haematol. 2006;136:379-392.
68.
Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98:29-35.
69.
Szankasi P, Bahler DW. Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis. J Mol Diagn. 2010;12:244-249.
70.
Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971-2979.